From lab to bedside: How AI-led consulting is closing the gap

In the quiet hum of an oncology ward, an infusion finishes and a patient’s electronic health record updates instantly. Down the hall, physicians glance at dashboards fed by a prediction engine that estimates her likelihood of responding to treatment. Miles away, in a consulting office lined with screens, a team tracks live operations data from multiple sites, helping ensure the therapy she receives today can be produced, shipped and ready for the next patient who needs it.

This is the practical reality behind healthcare transformation. It is also the context in which AI is moving from experimentation to an operating requirement. 

According to ZS’s 2025 Future of Health report, healthcare is changing under the weight of two parallel shifts: demand is stretching already burdened systems, and consumers now expect care to feel more accessible and convenient. 

At the same time, the World Health Organisation estimates a global shortage of 2 million doctors. The result is a system being pushed to evolve faster than ever. 

AI’s Growing Presence

In labs and research centres, AI is threading itself through the care continuum. In drug discovery, AI can analyse genetic and other biological data to spot disease signals that routine tests may miss, helping researchers develop more targeted treatments. As those therapies move through development, tools such as digital twins and trial design simulations could eventually cut clinical trial costs by as much as 60% and shorten cycle times by up to 40% as adoption expands.

AI’s role does not stop at the lab. It is also beginning to change how care is delivered and how healthcare systems respond to patient needs. 

According to the ZS report, 38% of consumers said they would share personal health data to receive tailored health services. That opens the door to more predictive, personalised models of care. 

Meanwhile, AI is reshaping the industry’s operational backbone. Predictive models forecast demand swings, reroute supply lines and monitor cold-chain integrity in real time. For temperature-sensitive biologics, these systems can mean the difference between a viable therapy and a product lost in transit. 

Yet these capabilities reach their full potential only when paired with deep domain expertise to align them with science, regulation and patient needs. That expertise is now the differentiator.

Back in the consulting room, as AI transforms healthcare delivery, it is also reshaping the consulting model that supports it. The traditional pyramid, with analysts sourcing and processing data, managers synthesizing and partners advising, is giving way to something leaner and more dynamic. 

Intelligent systems now handle much of the foundational work, freeing consultants to focus on decisions that require human judgment. What to prioritise, where to push, and when the science meets the market.

When Consulting and AI Converge

Imagine a next‑generation oncology biologic approaching launch. AI pinpoints manufacturing choke points months in advance, models distribution scenarios under different regulatory environments and analyses trial data for diversity compliance. 

The consulting team steps in to turn those projections into executable plans: sequencing production schedules with built‑in contingencies, aligning submissions across markets and shaping engagement strategies for prescribers.

Dynamic, targeted interactions with healthcare providers can be twice as effective as other forms of outreach, making engagement more relevant while lifting top-line brand sales by 5%-10%.  

AI helps enable that precision by identifying the “next best” actions, while consulting teams turn those prompts into strategies that are relevant, acceptable and timed to market dynamics. The result: machines set the ceiling, consultants decide how high to reach.

Embedding value into healthcare

The greatest impact of consulting comes from integration. Drug discovery delivers little to patients without reliable manufacturing. Manufacturing falters without secure distribution. Distribution matters only if providers can prescribe the therapy to the right patients at the right time. AI offers connective tissue, including tracking, predicting and adjusting, but consulting links it all back to strategic intent.

Consider what this looks like in practice. When a top cell therapy manufacturer faced low yield rates, the problem wasn't the science. It was the gap between what the process data captured and what supply planning assumed. 

A consulting team embedded AI-driven process monitoring into the manufacturing workflow, then connected its outputs directly to demand forecasting and distribution sequencing. Yield stabilised, and patient wait times dropped. No single AI tool achieved the desirable outcome. The integration did.

Take a top 10 pharma company projecting roughly $1 billion in AI-driven R&D savings over five years by running smarter trial simulations, failing faster on weak candidates, and cutting redundant late-stage spend. 

Those savings are real. But they accrue inside the lab. Getting them to move the needle for patients requires what no simulation can provide. Human judgment about where to push, when to pause, and how to connect a lab result to a market reality.

With ageing populations, regulatory complexity and the relentless pace of scientific change, the sector needs more than point solutions. 

Consulting firms are uniquely placed to help clients embed AI inside secure, auditable frameworks that win regulator trust and to design workflows around decision‑making rather than experimentation. The advantage goes to those who can combine deep therapeutic knowledge with fluency in digital tools, not to automate judgment, but to make it faster, sharper and more consequential.

Consumers have been clear about what they want: faster, more accurate diagnoses; affordable care; and the ability to access it anywhere, anytime. 

AI-led consulting is built to deliver on all three, not by replacing human intelligence but by scaling and sharpening it. The oncology ward doesn't care about the algorithm. It cares whether the next patient gets the right drug, on time, at a price the system can bear. That's the only metric that matters, and it's the one AI-led consulting is now built to move.